Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Liver Disease

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cld.2015.10.006PMID 27063269
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Radiological Clinical Practice Guidelines Published in the Last Decade: A Bibliometric Analysis

  2019cited by this paper
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

  2018cited by this paper
• A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains

  2017cited by this paper
• Non-alcoholic fatty liver disease: An expanded review

  2017cited by this paper
• Drug-induced steatohepatitis

  2017cited by this paper
• Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy.

  2015cited by this paper
• Use of liver breath tests to assess severity of nonalcoholic fatty liver disease.

  2015cited by this paper
• Validation of noninvasive methods for detecting hepatic steatosis in patients with human immunodeficiency virus infection.

  2015cited by this paper
• Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

  2015cited by this paper
• Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study

  2014cited by this paper
• Radiologic evaluation of nonalcoholic fatty liver disease.

  2014cited by this paper
• Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria

  2014cited by this paper
• Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments

  2014cited by this paper
• Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease

  2014cited by this paper
• Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.

  2014cited by this paper
• Noninvasive evaluation of NAFLD

  2013cited by this paper
• The Natural History of NAFLD

  2013cited by this paper
• External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study.

  2013cited by this paper
• EFSUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography. Part 1: Basic Principles and Technology

  2013cited by this paper
• Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals

  2013cited by this paper
• Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients

  2013cited by this paper
• Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study.

  2013cited by this paper
• Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.

  2013cited by this paper
• Meta‐analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis

  2013cited by this paper
• Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.

  2013cited by this paper
• Drug-induced steatohepatitis.

  2013cited by this paper
• Ectopic fat: the true culprit linking obesity and cardiovascular disease?

  2013cited by this paper
• Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States

  2012cited by this paper
• Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2012

  2012cited by this paper
• The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease

  2012cited by this paper
• Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

  2012cited by this paper
• Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data

  2012cited by this paper
• Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients

  2012cited by this paper
• Ultrasound‐based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: A systematic review and meta‐analysis

  2012cited by this paper
• Non‐invasive estimation of liver fibrosis in non‐alcoholic fatty liver disease using the 13C‐caffeine breath test

  2011cited by this paper
• The non-invasive 13C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis

  2011cited by this paper
• Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

  2011cited by this paper
• Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease.

  2011cited by this paper
• Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity.

  2011cited by this paper
• Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography.

  2011cited by this paper
• Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

  2011cited by this paper
• Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality

  2011cited by this paper
• A simple index of lipid overaccumulation is a good marker of liver steatosis

  2010cited by this paper
• Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up

  2010cited by this paper
• Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

  2010cited by this paper
• Cytokeratin‐18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study

  2009cited by this paper
• Comparison of blood tests for liver fibrosis specific or not to NAFLD.

  2009cited by this paper
• Liver biopsy

  2009cited by this paper
• Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus

  2009cited by this paper
• Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.

  2009cited by this paper
• Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease.

  2009cited by this paper
• Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects

  2008cited by this paper
• Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease

  2008cited by this paper
• Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes

  2008cited by this paper
• The epidemiology of nonalcoholic fatty liver disease: a global perspective.

  2008cited by this paper
• Magnetic resonance elastography for the noninvasive staging of liver fibrosis.

  2008cited by this paper
• The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

  2007cited by this paper
• Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

  2007cited by this paper
• Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

  2007cited by this paper
• The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome

  2007cited by this paper
• Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.

  2007cited by this paper
• Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center.

  2007cited by this paper
• Interobserver and intraobserver variability in the sonographic assessment of fatty liver.

  2007cited by this paper
• Meta-analyses of FibroTest diagnostic value in chronic liver disease

  2007cited by this paper
• Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients

  2007cited by this paper
• Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

  2006cited by this paper
• In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease

  2006cited by this paper
• Utility of a new model to diagnose an alcohol basis for steatohepatitis.

  2006cited by this paper
• The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

  2005cited by this paper
• Symptoms of Obstructive Sleep Apnea in Patients with Nonalcoholic Fatty Liver Disease

  2005cited by this paper
• Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.

  2005cited by this paper
• Serum markers detect the presence of liver fibrosis: a cohort study.

  2004cited by this paper
• Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity

  2004cited by this paper
• Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.

  2004cited by this paper
• Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

  2003cited by this paper
• Drug-induced steatohepatitis.

  2003cited by this paper
• Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients.

  2003cited by this paper
• Drugs and Steatohepatitis

  2002cited by this paper
• Nonalcoholic fatty liver disease.

  2002cited by this paper
• Selection and outcome of living donors for adult to adult right lobe transplantation.

  2000cited by this paper
• Fatty Infiltration of Liver in Hyperlipidemic Patients

  2000cited by this paper
• What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy.

  1997cited by this paper
• An algorithm for the grading of activity in chronic hepatitis C

  1996cited by this paper
• Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

  1980cited by this paper

• Suppression of nonalcoholic fatty liver disease by thymoquinone associated with inhibition of miRNA-155/ROS/p53/TIMP-1-mediated fibrosis and autophagy upregulation

  2026cites this paper
• The global cardiovascular-liver-metabolic syndemic: epidemiology, trends and challenges.

  2025cites this paper
• Preclinical research in obesity-associated metabolic diseases using in vitro, multicellular, and non-mammalian models

  2025cites this paper
• The Development of a Non-Invasive Screening Method Based on Serum microRNAs to Quantify the Percentage of Liver Steatosis

  2024cites this paper
• Principales fonctions hépatiques

  2023cites this paper
• CT Texture Analysis in Nonalcoholic Fatty Liver Disease (NAFLD).

  2023cites this paper
• Clinical Profile of Nonalcoholic Fatty Liver Disease and its Correlation with Metabolic Syndrome and Cardiovascular Risk

  2023cites this paper
• Hígado graso (parte 2): enfoque clínico y tratamiento

  2023cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective

  2023cites this paper
• Psoraleae Fructus Ethanol Extract Induced Hepatotoxicity via Impaired Lipid Metabolism Caused by Disruption of Fatty Acid β-Oxidation

  2023cites this paper
• Hígado graso (parte 1): aspectos generales, epidemiología, fisiopatología e historia natural

  2022cites this paper
• Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial

  2022cites this paper
• Metabolic determinants of NAFLD in adults with type 1 diabetes.

  2022cites this paper
• Metabolic Syndrome Severity Predicts Mortality in Nonalcoholic Fatty Liver Disease

  2022cites this paper
• Updates in the Epidemiology of Fatty Liver and its Consequences in Saudi Arabia: A Review

  2022cites this paper
• Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment

  2022cites this paper
• Non-alcoholic fatty liver disease part 1: general aspects, epidemiology. pathophysiology and natural history

  2022cites this paper
• Acupoint catgut-embedding therapy as promising treatment for non-alcoholic fatty liver disease

  2021cites this paper
• Safety and Effectiveness of Essential Phospholipids Paste in Patients with Non-alcoholic Fatty Liver Disease or Viral Hepatitis.

  2021cites this paper
• Non-Alcoholic Fatty Liver Disease in Cuba.

  2021cites this paper
• Enfermedad del hígado graso asociada con la disfunción metabólica. Una nueva propuesta para una dolencia en auge

  2021cites this paper
• Hígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa

  2020cites this paper
• Nonalcoholic Fatty Liver Disease, Male Sexual Dysfunction, and Infertility: Common Links, Common Problems.

  2020cites this paper
• Computed Tomography Measurements of Hepatic Steatosis in Cholelitihiasis and Cholecystectomy Cases Using Unenhanced Images.

  2020cites this paper
• Relationship Between Ginsenoside Rg3 and Metabolic Syndrome

  2020cites this paper
• Safety and Patient-Reported Outcomes in Non-Alcoholic FattyLiver Disease and Viral Hepatitis Patients Taking EssentialPhospholipids Paste as Adjunctive Treatment

  2020cites this paper
• ß-Hydroxybutyrate is Reduced in Humans with Obesity-Related NAFLD and Displays a Dose-Dependent Effect on Skeletal Muscle Mitochondrial Respiration In Vitro.

  2020cites this paper
• Improvement in Menopause-Associated Hepatic Lipid Metabolic Disorders by Herbal Formula HPC03 on Ovariectomized Rats

  2020cites this paper
• MEHP/ethanol co-exposure favors the death of steatotic hepatocytes, possibly through CYP4A and ADH involvement.

  2020cites this paper
• Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease

  2020cites this paper
• Primary Versus Secondary NAFLD: Perspective on Advanced Fibrosis.

  2020cites this paper
• A microfluidic patterned model of non-alcoholic fatty liver disease: applications to disease progression and zonation.

  2019cites this paper
• Fatty Liver Disease: A Practical Approach.

  2019cites this paper
• Radiologic Imaging in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

  2018cites this paper
• Alteration of fatty infiltration grades of the liver in sonography as an outcome of cholecystectomy

  2018influential citation
• Butein protects the nonalcoholic fatty liver through mitochondrial reactive oxygen species attenuation in rats

  2018cites this paper
• Hepatocellular Carcinoma: Known and Emerging Risk Factors

  2018cites this paper
• Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind.

  2017cites this paper
• Drug-induced steatohepatitis

  2017cites this paper
• GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice.

  2017cites this paper
• Non-alcoholic fatty liver disease: An expanded review

  2017cites this paper
• A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains

  2017cites this paper
• Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions

  2016cites this paper
• Fatty Liver (part 2): Clinical Approach and Treatment

  year unknowncites this paper